Search

Yogesh Arun Dound,1 Rajesh Sehgal2 1Research and Development, Shreepad Shree Vallabh SSV Phytopharmaceuticals, Mumbai, Maharashtra, India; 2Research and Development, Pharma Instinct Pvt. Ltd, Noida, Uttar Pradesh, IndiaCorrespondence: Yogesh Arun DoundResearch and Development, Shreepad Shree Vallabh SSV Phytopharmaceuticals, 201/2, Old Kashmiri Building, R R Thakur Marg, Majaswadi, Jogeshwari, Mumbai, Mahrashtra, 400060, IndiaEmail yogesh_dound@yahoo.comBackground: Recent viral pandemics have challenged the global scientific community to immediately develop new therapies. The fastest approach to develop these is to explore natural products for their efficacies and repurposing of already approved molecules. Keeping global emergency in view, researchers at Shreepad Shree Vallabh SSV Phytopharmaceuticals developed the CurvicTM (SSV-003) formulation, comprising of curcumin, vitamin C, vitamin K2-7, selenomethionine and Zinc.Methods: Researchers have systematically studied the SSV-003 formulation for its in vitro efficacy against influenza A virus (H1N1) (ATCC® VR-219™) and human beta coronavirus (ATCC® VR1558™) using MDCK & HCT-8 cell lines, respectively, in vivo efficacy studies of SSV-003 on influenza A virus infected Balb/c mice, and acute toxicity studies as per OECD guidelines.Results: Formulation SSV-003 showed potent antiviral activities against both the selected virus strains. Its IC50 was significantly lessthan ribavirin against influenza A-H1N1-VR219, with no cytopathic effect. SSV-003 showed IC50 of 2.26 μg/mL against human beta coronavirus, which was near to the IC50 of ribavirin (2.25 μg/mL) and was less than remedisivir (6.23 μg/mL) with no cytopathic effect. In-vivo studies in an influenza A virus infected mice model showed a significantly higher TCID50 value in the infected control group as compared to test groups. Animals treated with SSV-003 showed a dose dependent decrease in TCID50. Formulation SSV-003 at the dose of 500, 1,000, and 1,50